JP2024539385A5 - - Google Patents
Info
- Publication number
- JP2024539385A5 JP2024539385A5 JP2024526649A JP2024526649A JP2024539385A5 JP 2024539385 A5 JP2024539385 A5 JP 2024539385A5 JP 2024526649 A JP2024526649 A JP 2024526649A JP 2024526649 A JP2024526649 A JP 2024526649A JP 2024539385 A5 JP2024539385 A5 JP 2024539385A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- cancer
- compounds
- following
- haloethylamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2021/129077 WO2023077452A1 (zh) | 2021-11-05 | 2021-11-05 | Akr1c3活化的dna烷化剂及其医药用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024539385A JP2024539385A (ja) | 2024-10-28 |
| JP2024539385A5 true JP2024539385A5 (https=) | 2024-11-13 |
Family
ID=86240506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024526649A Pending JP2024539385A (ja) | 2021-11-05 | 2021-11-05 | Ａｋｒ１ｃ３活性化ｄｎａアルキル化剤、およびその医学的応用 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP4428138A4 (https=) |
| JP (1) | JP2024539385A (https=) |
| KR (1) | KR20240110013A (https=) |
| CN (1) | CN118201940A (https=) |
| TW (1) | TW202320804A (https=) |
| WO (1) | WO2023077452A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114106042B (zh) * | 2021-11-12 | 2022-09-16 | 深圳艾欣达伟医药科技有限公司 | 一种氘代化合物及其制备方法和应用 |
| KR20260009356A (ko) | 2023-05-11 | 2026-01-19 | 아센타위츠 파마슈티컬즈 리미티드 | 주사액 제제 및 이의 제조 방법, 및 상용성 약액 및 이의 제조 방법 |
| WO2025140580A1 (zh) * | 2023-12-28 | 2025-07-03 | 深圳艾欣达伟医药科技有限公司 | 化合物晶型 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI674258B (zh) * | 2015-03-10 | 2019-10-11 | 大陸商深圳艾欣達偉醫藥科技有限公司 | Ｄｎａ烷化劑 |
| WO2016161342A2 (en) * | 2015-04-02 | 2016-10-06 | Threshold Pharmaceuticals, Inc. | Nitrobenzyl derivatives of anti-cancer agents |
| EP3390415B1 (en) * | 2015-11-16 | 2020-02-26 | Obi Pharma, Inc. | (r)- and (s)-1-(3-(3-n,n-dimethylaminocarbonyl)phenoxyl-4-nitrophenyl)-1-ethyl-n,n'-bis (ethylene)phosphoramidate, compositions and methods for their use and preparation |
| WO2020228685A1 (zh) * | 2019-05-13 | 2020-11-19 | 深圳艾欣达伟医药科技有限公司 | 含氟化合物及抗癌医药用途 |
| US20220387345A1 (en) * | 2019-11-01 | 2022-12-08 | Ascentawits Pharmaceuticals, Ltd. | Anti-cancer compounds acting as non-pgp substrate |
| TWI837402B (zh) * | 2019-12-20 | 2024-04-01 | 大陸商深圳艾欣達偉醫藥科技有限公司 | 含氟化合物、含氟化合物之製備方法及其抗癌醫藥用途 |
-
2021
- 2021-11-05 EP EP21962965.6A patent/EP4428138A4/en active Pending
- 2021-11-05 CN CN202180103860.6A patent/CN118201940A/zh active Pending
- 2021-11-05 JP JP2024526649A patent/JP2024539385A/ja active Pending
- 2021-11-05 KR KR1020247018893A patent/KR20240110013A/ko active Pending
- 2021-11-05 WO PCT/CN2021/129077 patent/WO2023077452A1/zh not_active Ceased
-
2022
- 2022-11-04 TW TW111142123A patent/TW202320804A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024539385A5 (https=) | ||
| JP2023542286A5 (https=) | ||
| US20210386873A1 (en) | Precursor compound of radioactive halogen-labeled organic compound | |
| EP2970123B1 (en) | Salt of omecamtiv mecarbil and process for preparing salt | |
| EP4043455A1 (en) | Bicyclic compound that acts as crbn protein regulator | |
| TWI458494B (zh) | Radioactive fluorine labeling organic compounds manufacturing methods (a) | |
| TW201837044A (zh) | 製備苯并氧氮呯(benzoxazepin)噁唑啶酮化合物之方法 | |
| WO2017045582A1 (zh) | 核苷氨基磷酸酯类前药的制备方法及其中间体 | |
| US20090076042A1 (en) | Deuterium-enriched erlotinib | |
| WO2014109256A1 (ja) | トリアゾール連結型環状ジヌクレオチド類縁体 | |
| JP3776799B2 (ja) | 五環性タキサン化合物 | |
| US8030338B2 (en) | Method for producing 2-nitroimidazole derivative | |
| JP2019151666A (ja) | アナグレリドおよびその類似体の調製のためのプロセス | |
| JP2809145B2 (ja) | 含フッ素コリン化合物の１８ｆ標識体、その製造方法および陽電子断層撮影診断用試薬としての応用 | |
| WO2009075504A2 (en) | Crystalline form of bepotastine p-toluenesulfonate, method for preparing same and pharmaceutical composition containing same | |
| CN112707869B (zh) | 一种达可替尼杂质及其制备方法 | |
| WO2024234619A1 (zh) | 一种化合物的晶型、药物组合物及用途 | |
| CN119264131A (zh) | Nmt抑制剂及其制备方法和用途 | |
| CN114286811B (zh) | 富马酸单甲酯的前药 | |
| WO2025223583A1 (en) | Ptpn2/ptp1b degrader and synthesis methods thereof | |
| CN1469863A (zh) | 1-[6-氯-5-(三氟甲基)-2-吡啶基]哌嗪盐酸盐的晶形 | |
| CN114380783B (zh) | 一种奥洛他定氘标记代谢物的制备方法 | |
| WO2026040159A1 (zh) | 一种肺癌细胞靶向治疗药物及其制备方法 | |
| CN119912397A (zh) | 一种吉非替尼中间体杂质ykyz-c-gf-3及其制备方法和控制方法 | |
| CN121085929A (zh) | 一种巴瑞克替尼与酸结晶形式及其制备方法 |